Compounded vs Branded GLP-1: What's the Real Difference?
Wegovy, Zepbound, and compounded semaglutide all contain the same active molecule — but they're not the same product. Here's what changes and what doesn't.
The GLP-1 shortage of 2022–2024 made compounded semaglutide and tirzepatide widely available. As supply has normalized, the regulatory landscape has shifted — and so has the choice.
What "compounded" actually means
A compounded medication is prepared by a licensed pharmacy for a specific patient prescription. In the U.S., 503A pharmacies compound on a per-patient basis; 503B outsourcing facilities produce larger batches under FDA oversight similar to manufacturers.
Why compounded GLP-1 exists
When the FDA declares a medication in shortage, compounders may legally prepare an equivalent formulation. Semaglutide and tirzepatide were both on the shortage list during the demand surge, opening the door to compounded versions at a fraction of brand pricing.
Where shortage status stands now
The FDA removed tirzepatide from the shortage list in late 2024 and semaglutide in early 2025. Reputable telehealth practices have since shifted toward branded medications where indicated, with compounded options used selectively for patients with documented clinical justification (e.g., dose strengths not commercially available).
What's the same
The active pharmaceutical ingredient — semaglutide or tirzepatide — is chemically identical when sourced from FDA-registered suppliers. The mechanism, indications, and clinical effects do not change.
What's different
Excipients (the inactive ingredients), preservation systems, packaging, and quality oversight differ. A compounded preparation may include additives like B12 or B6 that are not in the branded product; some patients prefer this, some don't. Cost is the largest practical difference — branded GLP-1 retails for $1,000–$1,400 per month; compounded preparations typically run $250–$500.
How to evaluate a compounding pharmacy
Ask for the pharmacy's state license number, NABP accreditation status, and whether they are 503A or 503B. Ask where the active ingredient is sourced. A reputable practice answers these questions in writing without hesitation.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.FDA Drug Shortages: Tirzepatide Injection Resolution.— U.S. Food and Drug Administration, 2024.
- 2.FDA: Compounding and the FDA — Questions and Answers.— U.S. Food and Drug Administration, 2024.
- 3.National Association of Boards of Pharmacy (NABP) Verified Pharmacy Program.— NABP, 2024.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
